Indian Pharma giant has Responded to the complaint filed by US regulatory agency. Regulatory agency in its complaint has alleged that Ranbaxy declined to provide internal Audit report from consulting audit firm Parexel (citing attorney client privilege) w.r.t their assessment of deficiencies in Ranbaxy’s Paonta sahib Plant.
Ranbaxy filed its reply to the Maryland district court and has agreed to provide all documents to investigating agency. Ranbaxy also released a press release where it clarifies that USFDA over the last 3 yeras has checked around 200 samples of various generic products, and all samples conform to regulatory standards.
Ranbaxy announced that there will be no change in its deal with Daiichi.
Ranbaxy shares also fall in stock market and Ranbaxy has alleged that there are elements who are affecting its market stock here.
IP Pharma Doc believes that Ranbaxy can successfully defend the allegation
Also, mint has reported on possible harm in the reputation of indian generic players in US market due to Ranbaxy Controversy here.
Wednesday, 16 July 2008
Ranbaxy ready to share inernal audit report with USFDA
Subscribe to:
Post Comments (Atom)
1 comment:
Sir, the work done by you is highly commendable. All the necessary updates are available in the website.
I again wish you luck for your endeavours.
Regards,
Inderjit
Post a Comment